French drugmaker Sanofi on Monday flagged another delay to a U.S. regulatory decision for its experimental multiple sclerosis ...

FDA has given tentative approval to Lupin’s Siponimod tablets, a bioequivalent version of Mayzent, to treat people with ...

Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple ...

A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of ...

French pharmaceutical group Sanofi said on Monday ‍the U.S. Food and Drug Administration's decision on its investigative drug ...

Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the ...

Zeposia (ozanimod) is a prescription drug used to treat certain forms of multiple sclerosis (MS) in adults. Zeposia is a brand-name drug and is not currently available in a generic version. Zeposia ...

Improvements in safety, efficacy, and specificity have raised questions around the benefits and risks of switching treatments for this type of MS, especially from fingolimod to siponimod. There are ...

Thousands of Australians battling a debilitating form of multiple sclerosis have been granted a reprieve, as a groundbreaking injection treatment is added to Australia’s Pharmaceutical Benefits Scheme ...

As of 2022, there were 15 oral and injectable MS drugs across seven types of "classes," or groups of medication that work in similar ways. These treatments are all pricey, usually costing $5,000 to ...